• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$3.64 -$0.01 (-0.27%)

REAL-TIME: Last trade at

Dynavax Technologies Corp

NASDAQ:DVAX

Jump to this page for:

Related Resources

Dynavax Shares Fall as CEO to Leave, Issues Stock

5/10/2012 by Pharmaceutical Processing

Dynavax shares fall as CEO to leave, issues stock

5/9/2012 by Bioscience Technology

Dynavax falls 24%

5/9/2012 by Theflyonthewall.com

Dynavax falls 20.6%

5/9/2012 by Theflyonthewall.com

Dynavax falls 17.1%

5/9/2012 by Theflyonthewall.com

Dynavax 17.5M share Spot Secondary priced at $4.25

5/9/2012 by Theflyonthewall.com

Dynavax (CVAX) Prices 17.5M Offering at $4.25/Share

5/9/2012 by StreetInsider.com

Dynavax Prices Public Offering of Common Stock

5/9/2012 by Marketwire

Disney, Dynavax, SodaStream: U.S. Equity Market Preview

5/9/2012 by Bloomberg.com

Dynavax files to sell common stock, no amount given

5/8/2012 by Theflyonthewall.com

Dynavax Embarks on Transition to Commercialization

5/8/2012 by Marketwire

Dynavax Announces Proposed Public Offering of Common Stock

5/8/2012 by Marketwire

Dynavax: Let The Show Begin!

4/30/2012 by Seeking Alpha

Dynavax Technologies Corp (DVAX) Misses Q1 EPS by 1c

4/27/2012 by StreetInsider.com

Dynavax reports Q1 EPS (11c), consensus (10c)

4/27/2012 by Theflyonthewall.com

Dynavax Reports First Quarter 2012 Financial Results

4/27/2012 by Marketwire

Dynavax Technologies Corporation Reports HEPLISAV(TM) BLA Submission

4/27/2012 by BioSpace

Dynavax reports Heplisav BLA submission

4/26/2012 by Theflyonthewall.com

Dynavax Reports HEPLISAV(TM) BLA Submission

4/26/2012 by Marketwire

Jefferies Maintains Bullish Stance on Dynavax (DVAX) On Heplisav CKD Data Update

3/28/2012 by StreetInsider.com

Dynavax (DVAX) Reports Positive Final Data From Chronic Kidney Disease Trial

3/27/2012 by iStockAnalyst

Dynavax reports final Phase 3 data for HEPLISAV

3/27/2012 by Theflyonthewall.com

Dynavax Reports Final Phase 3 Data for HEPLISAV(TM) in CKD Patients and New Data From Booster Trial in Hemodialysis Patients

3/27/2012 by Marketwire

Phase 3 Data on HEPLISAV(TM) in Adults Aged 40-70 Published in VACCINE

3/13/2012 by Genetic Engineering News

Dynavax says Phase 3 data on Heplisav in adults 40-70 published in VACCINE

3/13/2012 by Theflyonthewall.com

Phase 3 Data on HEPLISAV(TM) in Adults Aged 40-70 Published in VACCINE

3/13/2012 by Marketwire

Dynavax posts smaller 4Q loss as payments increase

3/6/2012 by Canadian Business - Canada

Dynavax reports Q4 EPS (3c), consensus (7c)

3/6/2012 by Theflyonthewall.com

Dynavax Technologies Corp (DVAX) Posts Q4 Loss of 3c/Share

3/6/2012 by StreetInsider.com

Dynavax Reports Fourth Quarter and Year End 2011 Financial Results

3/6/2012 by Marketwire

SAC Capital raises passive stake in Dynavax to 5.1%

3/5/2012 by Theflyonthewall.com

SAC Capital Raises Stake in Dynavax Technologies Corporation (DVAX) to 6.2%

3/5/2012 by StreetInsider.com

Dynavax: HEPLISAV BLA Submission On Track For May 2012

2/27/2012 by Seeking Alpha

Institutional and Inside Buyers Are Buying Stocks Under $5 (CLWR, SNV, CMLS, DVAX)

2/22/2012 by Investopedia

Dynavax to Present at Two Upcoming Investor Healthcare Conferences

2/14/2012 by Marketwire

Dynavax Technologies Corporation Release: Phase 3 Data on HEPLISAV(TM) in Adults Aged 18-55 Published in

2/13/2012 by BioSpace

Dynavax Heplislav Phase lll data published in Vaccine

2/13/2012 by Theflyonthewall.com

Phase 3 Data on HEPLISAV(TM) in Adults Aged 18-55 Published in VACCINE

2/13/2012 by Marketwire

Jefferies Lowers Numbers on Dynavax (DVOX), Keeps "Buy" Rating

2/9/2012 by StreetInsider.com

Jefferies Maintains a 'Buy' on Dynavax Technologies (DVAX); Broad Adult Label Should Be A Positive For Heplisav and Diabetes Opportunity

2/3/2012 by StreetInsider.com
See More Articles...